Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,883
Employees75,883
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,883
Employees75,883

NVS Key Statistics

Market cap
275.90B
Market cap275.90B
Price-Earnings ratio
17.66
Price-Earnings ratio17.66
Dividend yield
2.51%
Dividend yield2.51%
Average volume
1.85M
Average volume1.85M
High today
$130.76
High today$130.76
Low today
$130.65
Low today$130.65
Open price
$130.16
Open price$130.16
Volume
5.63K
Volume5.63K
52 Week high
$134.00
52 Week high$134.00
52 Week low
$96.06
52 Week low$96.06

Stock Snapshot

Novartis(NVS) stock is priced at $130.68, giving the company a market capitalization of 275.9B. It carries a P/E multiple of 17.66 and pays a dividend yield of 2.5%.

As of 2025-12-01, Novartis(NVS) stock has fluctuated between $130.65 and $130.76. The current price stands at $130.68, placing the stock +0.0% above today's low and -0.1% off the high.

Novartis(NVS) shares are trading with a volume of 5.63K, against a daily average of 1.85M.

In the last year, Novartis(NVS) shares hit a 52-week high of $134.00 and a 52-week low of $96.06.

In the last year, Novartis(NVS) shares hit a 52-week high of $134.00 and a 52-week low of $96.06.

NVS News

Nasdaq 6d
Why Novartis Stock Topped the Market Today

Key Points It earned FDA approval for a spinal muscular atrophy drug. This is a version of its existing commercialized SMA treatment, Zolgensma. 10 stocks we...

Why Novartis Stock Topped the Market Today
Benzinga 6d
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

On Monday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Itvisma (onasemnogene abeparvovec-brve) for children two years and olde...

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults
TipRanks 6d
Novartis Gains FDA Approval for Groundbreaking SMA Gene Therapy

TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to Tip...

Analyst ratings

53%

of 30 ratings
Buy
30%
Hold
53.3%
Sell
16.7%

More NVS News

TipRanks 6d
Novartis upgraded to Buy from Neutral at BofA

BofA upgraded Novartis (NVS) to Buy from Neutral with a price target of CHF 117, up from CHF 111. A long-standing overhang for investors has been the company’s...

TipRanks 6d
Novartis AG: Strong Growth Potential Amid Patent Expirations with Robust Pipeline and Strategic Phase III Trials

In a report released today, Sachin Jain from Bank of America Securities upgraded Novartis AG to a Buy, with a price target of CHF117.00. TipRanks Black Friday S...

TipRanks 7d
Novartis receives FDA approval for Itvisma

Novartis (NVS) “announced that the US Food and Drug Administration has approved Itvisma, onasemnogene abeparvovec-brve, for the treatment of children two years...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.